UKALL60+: identifying the standard of care for elderly patients with ALL
PT-1 study update: addition of hydroxyurea to aspirin in essential thrombocythemia
A RESPONSE to ruxolitinib: update on 4-year trial follow-up
The challenges facing elderly AML treatment
T-cell engaging antibodies: what lessons have we learnt?